Fabhalta C3 glomerulopathy treatment Gains EMA ...

By João L. Carapinha

March 4, 2025

Have you heard the latest on treatment options for rare kidney diseases? Novartis' Fabhalta (iptacopan) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This is for the Fab...
Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis
Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients
Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaborati...
ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary S...
Global Childhood Cancer Access
New Global AIDS Strategy 2030 Aims to End AIDS Threat by 2030
Hypertension Detection: HTN-AI Model for Cardiovascular Risk Stratification
CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps
Lenacapavir HIV Prevention: Approval and Access Strategy Updates
Strengthening Africa Health Partnership
Urgent Call for Enhanced Breast Cancer Africa Control Measures
Journavx Pain Management: FDA Approves New Non-Opioid Treatment for Acute Pain